Lv11
44 积分 2024-07-02 加入
IRF4 in multiple myeloma—Biology, disease and therapeutic target
46分钟前
已完结
Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
55分钟前
求助中
IRF4 addiction in multiple myeloma
57分钟前
已完结
Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA × Murine anti-[In-DTPA] Bispecific Antibody Construct and a 99mTc-/188Re-Labeled Peptide
1个月前
已完结
New payloads drive next-gen antibody–drug conjugates
1个月前
已完结
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial
1个月前
已完结
Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells
1个月前
已完结
Design, Synthesis, and Biological Evaluation of Isoform-Selective Akt3 Degraders
1个月前
已完结
Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity
1个月前
已完结
Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
1个月前
已完结
皖公网安备34019202002308
